Advanced in Ulcerative Colitis

Crispin J. Corte

Hospital Rd, 
Concord, NSW, AU 
Advanced in Ulcerative Colitis
Hospital Rd, 
Concord, NSW, AU 
OverviewLocationsClinical Research

Overview

Crispin Corte practices in Concord, Australia. Mr. Corte is rated as an Advanced expert by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Ulcerative Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 2 clinical trials in the study of Ulcerative Colitis.

Gender
Male

Locations

Hospital Rd, Concord, NSW 2139, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

31 Total Publications

Editorial: Redefining Safety in Post-Liver Transplant IBD-Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply.
Editorial: Redefining Safety in Post-Liver Transplant IBD-Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: August 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Corte's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile